http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H01132520-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f8dbdfc93841b3d731fbab7ea48b412a |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D513-14 |
| filingDate | 1988-10-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c7e085a5d7571d6a423801d73283d900 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a5bf2ce5194ee114a23e0045db9809c |
| publicationDate | 1989-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H01132520-A |
| titleOfInvention | Composition for treating hyperlipemia |
| abstract | PURPOSE: To obtain the subject composition containing 11-oxo-11-pirido[2,1- b]quinazoline-2-carboxylic acid as an active ingredient with carrier, etc., capable of treating both of hyperlipemia and hyperuricemia and free from adverse effect. n CONSTITUTION: This composition contains 11-oxo-11-pirido[2,1-b]quinazolin-2- carboxylic acid or its salt as an active ingredient and usual carrier and/or addition. The composition is prepared in a tablet as follows. The active ingredient compound in an amount of 100g, 10g colloidal silica, 118g lactose, 60g potato starch, 6g polyvinyl-pyrrolidone, 4g sodium cellulose glycolate and 2g magnesium stearate are treated according to ordinary method to provide 300mg tablet. When using, the composition is preferably used in the form of oral administration, especially capsule form, but can be utilized also as the form of a tablet, a granule, etc. n COPYRIGHT: (C)1989,JPO |
| priorityDate | 1987-10-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 39.